Scoop has an Ethical Paywall
Scoop InfoPages
This InfoPage in unregistered, if this is your news page register PHARMAC for InfoPages here.
PHARMAC - Latest News [Page 14]
Papers reveal PHARMAC’s cautious approach with new drug
Monday, 31 October 2011, 3:35 pm | PHARMAC
Papers released by PHARMAC today outline the careful consideration given before funding was approved for the new-generation anticoagulant drug dabigatran (Pradaxa). Dabigatran, which belongs to a new class of drugs called direct thrombin inhibitors, was funded ... More >>
PHARMAC’s first regional consumer forum in Porirua
Friday, 14 October 2011, 2:06 pm | PHARMAC
PHARMAC and two members from its Consumer Advisory Committee, Shane Bradbrook and Anne Fitisemanu, will be hosting a lunchtime forum in Porirua on 25 October 2011. More >>
PHARMAC Board strengthens relationship with DHBs
Friday, 30 September 2011, 12:51 pm | PHARMAC
Getting closer to district health boards, on whose behalf PHARMAC aims to spend $777 million this year, took on a new meaning today. For the first time the PHARMAC Board’s monthly meeting was held outside Wellington. More >>
2011 Hiwinui Heke Scholarships Awarded
Saturday, 6 August 2011, 4:21 pm | PHARMAC
2011 Hiwinui Heke Scholarships Awarded Four high performing Maori pharmacy students will be awarded the prestigious Hiwinui Heke Māori Pharmacy Student Scholarship 2011 on Saturday 6 August at Te Unga Waka Marae in Epsom. More >>
PHARMAC widens access to two cancer drugs
Thursday, 28 July 2011, 2:02 pm | PHARMAC
In the first decision, PHARMAC has widened funded access to rituximab for chronic lymphocytic leukaemia (CLL) patients who have not had rituximab before, either as a first line treatment or where their disease has relapsed following up to three ... More >>
‘More permissive’ system follows PHARMAC review
Monday, 27 June 2011, 5:19 pm | PHARMAC
PHARMAC is moving to a more permissive and streamlined system for assessing people seeking medicines that aren’t funded on the Pharmaceutical Schedule. More >>
Two new treatments for bone-thinning disease
Thursday, 23 June 2011, 3:19 pm | PHARMAC
Raloxifene (Evista) and teriparatide (Forteo) will be fully funded following an agreement PHARMAC has reached with pharmaceutical company Eli Lilly. The agreement also includes a long-acting injectable form of the antipsychotic medicine olanzapine. More >>
Success in Tackling Indigenous Cardiovascular Disease
Friday, 17 June 2011, 3:20 pm | PHARMAC
A New Zealand preventative health campaign which has significantly improved take-up of cholesterol lowering medication among Maori and Pacific Island males sets the bar for Australia to develop its own initiatives to achieve similar outcomes for ... More >>
PHARMAC welcomes PTAC reappointment
Thursday, 16 June 2011, 2:13 pm | PHARMAC
PHARMAC is welcoming the reappointment of Waikato Hospital physician Dr Graham Mills to the Pharmacology and Therapeutics Advisory Committee (PTAC). More >>
'Game-changing' anti-clotting treatment funded
Tuesday, 14 June 2011, 9:51 am | PHARMAC
PHARMAC is funding an innovative form of anti-blood clotting treatment that will significantly change the way anticoagulation is managed in New Zealand. More >>
PHARMAC to fund new multiple myeloma treatments
Sunday, 1 May 2011, 3:01 pm | PHARMAC
May 1, 2011 Media release PHARMAC to fund new multiple myeloma treatments PHARMAC is enabling New Zealanders with multiple myeloma (MM) to benefit from early use of a new treatment, bortezomib (Velcade) as well as providing wider access to thalidomide, ... More >>
PHARMAC To Fund Sleep Disorder Treatment
Tuesday, 26 April 2011, 3:26 pm | PHARMAC
PHARMAC will fund a new treatment for the sleep disorder narcolepsy from 1 May 2011. Narcolepsy is a condition that causes people to be excessively drowsy during the day, or to fall asleep when they don’t expect to. More >>
PHARMAC reduces paperwork, expands access to Special Foods
Monday, 28 February 2011, 3:16 pm | PHARMAC
PHARMAC reduces paperwork, expands access to Special Foods Changes in access rules for funded special foods will see more prescribers able to supply funded special foods to patients. To date the funding rules for Special Foods, such as some types ... More >>
PHARMAC’s Consultation on Exceptional Circumstances
Monday, 10 January 2011, 2:43 pm | PHARMAC
PHARMAC is seeking feedback on proposed changes to its Exceptional Circumstances policy. Currently the three exceptional circumstances schemes provide pharmaceutical funding consideration for patients in rare or unusual medical situations, where there ... More >>
Three new members appointed to PHARMAC advisory committee
Wednesday, 22 December 2010, 3:44 pm | PHARMAC
PHARMAC is welcoming the appointment of three new members to the Pharmacology and Therapeutics Advisory Committee (PTAC). PTAC provides expert clinical advice on medicine funding applications being considered by PHARMAC. Acting Director-General of Health ... More >>
Adaptable approach key to success in hospitals
Wednesday, 15 December 2010, 11:52 am | PHARMAC
Learning from past experience will serve PHARMAC well as it takes a greater role in purchasing hospital medicines, says Chief Executive Matthew Brougham. The Government this year gave PHARMAC an expanded role in purchasing hospital medicines. PHARMAC ... More >>
Wider access to MS treatments
Monday, 29 November 2010, 10:25 am | PHARMAC
Government drug funder PHARMAC will provide wider access to treatments for multiple sclerosis (MS), and fund new blood-thinning and antibiotic treatments following an agreement with Bayer New Zealand Limited. More >>
Two further treatments for depression to be funded
Thursday, 25 November 2010, 10:44 am | PHARMAC
PHARMAC is adding two further treatments for depression to the Pharmaceutical Schedule from 1 December 2010. Sertraline and escitalopram are both being funded without restriction for patients with depression. Both medicines are of the antidepressant class known ... More >>
Brain Tumour Patients to Gain Greater Access to Temozolomide
Monday, 22 November 2010, 1:00 pm | PHARMAC
People with brain tumours are to have greater access to an expensive cancer drug from 1 December.Temozolomide (Temodal) has been funded since 2005 for patients newly diagnosed with the most advanced forms of brain tumour, called glioblastoma multiforme. More >>
New money leads to leap in availability of meds
Friday, 22 October 2010, 5:40 pm | PHARMAC
A $40 million lift in pharmaceutical spending has led to a significant rise in the number of medicines available to New Zealanders, and the number of people receiving them. More >>
